Abstract
We write this letter as an African HIV physician–scientist (NASA) and as an African health economist (ESKB) with combined in-depth experience in donor-funded HIV program implementation, sustainable health financing and donor funding transition. We read with great interest the Perspective article published on October 7, 2023 by Dow and Mmbaga, titled “Who Will Suffer Most if US AIDS Funding Ends” [ 1]. The article highlighted recent threats to the reauthorization of the President’s Emergency Plan for AIDS Relief (PEPFAR) by the United States Congress. The authors advocated for PEPFAR continuation on behalf of young Tanzanians living with HIV and other PEPFAR beneficiaries across Africa. PEPFAR is a bipartisan initiative established by Republican President George W. Bush’s administration in 2003, and has since provided over $100 billion in critical funding for HIV prevention, care, and treatment for millions of people in high-burden countries in Asia, Africa, and the Americas [ 2, 3]. In the absence of robust transition plans, discontinuations or significant reductions in funding would critically disrupt HIV services in many of these countries. This is due to the current (over)-reliance on PEPFAR funding for HIV interventions and the limited opportunities for health system financing in the current macro-fiscal environment.

This publication has 2 references indexed in Scilit: